942195-55-3
- Product Name：Tegoprazan
- Molecular Formula：C20H19F2N3O3
- Purity：99%
- Molecular Weight：0
Product Details:
CasNo： 942195-55-3
Molecular Formula： C20H19F2N3O3
Buy High Grade Tegoprazan,High Purity 942195-55-3 Best Price
- Molecular Formula:
- Molecular Weight:0
Tegoprazan(Cas 942195-55-3) Usage
|
Description |
Tegoprazan is a novel potassium-competitive acid blocker (P-CAB), designed as a next-generation therapeutic for the treatment of acid-related gastrointestinal diseases. These diseases include gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis (EE), and nonerosive reflux disease (NERD). |
|
Uses |
As a potassium-competitive acid blocker, Tegoprazan works by blocking the potassium-binding site of gastric H+/K+ ATPase, differentiating its mechanism from traditional proton pump inhibitors (PPIs). Tegoprazan has demonstrated stronger and more reversible gastric acid suppression compared to traditional PPIs. Tegoprazan received approval in South Korea in 2018 for the treatment of acid-related gastrointestinal diseases. It is marketed under the brand name K-CAB® by HK inno. N. In 2022, a sublicensee of HK inno. N launched Tegoprazan in China, the Philippines, and Mongolia, expanding its availability for patients in these regions. |
942195-55-3 Relevant articles
Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
JG Hwang, H Yoo, JW Lee, GS Song
TCP Transl Clin Pharmacol, 2019;27(2):80-85
As a new treatment option, potassium-competitive acid blockers (P-CABs), such as tegoprazan, have been developed. This study was performed to compare the pharmacokinetics (PKs) between two formulations (test and reference drugs) of tegoprazan 100 mg tablets …
Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects
Sungpil Han, Hee Youn Choi, Yo Han Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
Alimentary Pharmacology & Therapeutics, Volume50, Issue7 October 2019 Pages 751-759
A phase I, randomised, double-blind and placebo-controlled clinical trial was conducted in 56 healthy male subjects without Helicobacter pylori infection. In the single ascending dose study, 50, 100, 200 and 400 mg tegoprazan were administered to 32 subjects. In the multiple ascending dose study, 100 and 200 mg tegoprazan were administered every 24 hours to each of the eight subjects for 7 days.
Relevant Products
-
PralsetinibCAS：2097132-94-8
-
Avatrombopag maleateCAS：677007-74-8
-
Ixazomib citrateCAS：1201902-80-8
